Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Trial Comparing a Multi-Modal Pain Protocol With and Without Opioids Following Total Joint Arthroplasty

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03845881
Recruitment Status : Recruiting
First Posted : February 19, 2019
Last Update Posted : May 10, 2019
Sponsor:
Collaborators:
Ambit Biosciences Corporation
Kern Medical Center
Information provided by (Responsible Party):
Benjamin K. Wilke, Mayo Clinic

Brief Summary:
To help curb the use of opioid medications following orthopedic surgery investigators have developed a new multi-modal pain pathway. Investigators aim to compare this regimen with and without the inclusion of opioid medications. This study will be performed in a randomized, double-blinded, placebo-controlled fashion in patients undergoing primary total knee or total hip arthroplasty. Investigators hypothesize that the opioid devoid pathway will show equivalent pain scores to the pathway that includes opioids while also having less constipation, nausea, and vomiting following surgery. If successful, this would create a dramatic decrease in opioid consumption following orthopedic surgery while still providing appropriate pain relief to patients.

Condition or disease Intervention/treatment Phase
Total Knee Arthroplasty Drug: Oxycodone Drug: Placebo Oral Tablet Early Phase 1

Detailed Description:
  • Aim 1 will be to compare the postoperative pain levels both in the hospital setting as well as daily for two weeks following discharge between patients in the opioid treatment group and those in the non-opioid treatment group. This will be performed with clinical exams while in the hospital and with phone surveys on discharge. Results will be recorded using the Visual Analog Scale for pain scores.
  • Aim 2 will be to compare the overall morphine equivalents used during hospitalization between the opioid and non-opioid treatment groups. This will be calculated based on the amount of intravenous breakthrough narcotic pain medication used in the hospital setting (divided by the total number of post-surgery hospitalization hours to account for varying lengths of stay). Investigators will also measure the total number of opioid pills (these would be placebo pills for the non-opioid group) consumed during the first two weeks post-discharge, and the post-surgery day on which opioid pills were discontinued, and compare these outcomes between the opioid and non-opioid groups.
  • Aim 3 will be to compare postoperative constipation, nausea, and vomiting between the two treatment groups. This will be assessed with daily clinical examinations while in the hospital and with daily phone surveys on discharge. Constipation will be recorded as presence or absence, while nausea and vomiting will be measured using the Postoperative Nausea and Vomiting Scale.
  • Aim 4 will be to compare the length of post-surgery hospitalization between the two treatment groups.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Intervention Model Description: Multi-Modal Pain Protocol with and without Opioids Following Total Joint Arthroplasty
Masking: Double (Participant, Investigator)
Masking Description: The oxycodone and placebo tablets will be encapsulated by the research pharmacy prior to dispensing for blinding purposes.
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing a Multi-Modal Pain Protocol With and Without Opioids Following Total Joint Arthroplasty
Actual Study Start Date : April 10, 2019
Estimated Primary Completion Date : February 28, 2020
Estimated Study Completion Date : September 30, 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Oxycodone

Arm Intervention/treatment
Active Comparator: Opioid
Multi-Modal Pain Protocol with Opioids Following Total Joint Arthroplasty
Drug: Oxycodone
The primary endpoint will be pain scores, calculated by the Visual Analog Scale. This score will be collected daily during the hospital examination and by phone surveys for two weeks following discharge. Investigators hypothesize that the non-opioid pain regimen will provide equivalent relief as compared to the opioid regimen.

Placebo Comparator: Non Opioid
Multi-Modal Pain Protocol without Opioids Following Total Joint Arthroplasty
Drug: Placebo Oral Tablet
The primary endpoint will be pain scores, calculated by the Visual Analog Scale. This score will be collected daily during the hospital examination and by phone surveys for two weeks following discharge. Investigators hypothesize that the non-opioid pain regimen will provide equivalent relief as compared to the opioid regimen.




Primary Outcome Measures :
  1. Pain Levels [ Time Frame: 2 weeks ]
    compare the postoperative pain levels both in the hospital setting as well as daily for two weeks following discharge between patients in the opioid treatment group and those in the non-opioid treatment group. This will be performed with clinical exams while in the hospital and with phone surveys on discharge. Results will be recorded using the Visual Analog Scale for pain scores. This scale ranges from 0 to 10, with zero being no pain and 10 being as bad as can be, and includes visual facial cues. Following this scale, investigators will also ask about sleep, activity, mood, and stress.


Secondary Outcome Measures :
  1. Opioid Levels [ Time Frame: 2 weeks ]
    compare the overall morphine equivalents used during hospitalization between the opioid and non-opioid treatment groups. This will be calculated based on the amount of intravenous breakthrough narcotic pain medication used in the hospital setting (divided by the total number of post-surgery hospitalization hours to account for varying lengths of stay). Investigators will also measure the total number of opioid pills (these would be placebo pills for the non-opioid group) consumed during the first two weeks post-discharge, and the post-surgery day on which opioid pills were discontinued, and compare these outcomes between the opioid and non-opioid groups.

  2. Side effects [ Time Frame: 2 weeks ]
    compare postoperative constipation, nausea, and vomiting between the two treatment groups. This will be assessed with daily clinical examinations while in the hospital and with daily phone surveys on discharge. Constipation will be recorded as presence or absence, while nausea and vomiting will be measured using the Postoperative Nausea and Vomiting Scale. This scaled is based off 2 questions related to nausea and vomiting which will be added together for a total score. Responses range from 0 to 3 and a total score of greater than or equal to 5 will be defined as clinically important.

  3. Length of hospitalization [ Time Frame: 2 weeks ]
    compare the length of post-surgery hospitalization between the two treatment groups.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 89 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age > 18 and < 90 years.
  2. Willing to participate in the study and competent to provide informed consent.
  3. Willing to comply with protocol procedures.
  4. Has an underlying diagnosis of osteoarthritis indicated for knee arthroplasty.

Exclusion Criteria:

  1. A diagnosis of renal or liver disease
  2. If a patient has a contraindication to receiving a spinal anesthetic or pain catheter
  3. The patient must not have taken any narcotic medications during the 3 months leading up to the surgery
  4. The patient must not be allergic or intolerant to a medication used in the multi-modal pain pathway
  5. Revision hip or knee arthroplasty
  6. If a patient is being treated under worker's compensation
  7. If a patient has diabetes
  8. Unable to take Aspirin 325 mg twice daily for deep venous thromboprophylaxis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03845881


Contacts
Layout table for location contacts
Contact: Lori Chase, CCRP (904) 953-3464 Chase.Lori@mayo.edu

Locations
Layout table for location information
United States, Florida
Mayo Clinic in Florida Recruiting
Jacksonville, Florida, United States, 32224
Contact: Lori Chase, CCRP    904-953-3464    Chase.Lori@mayo.edu   
Sponsors and Collaborators
Mayo Clinic
Ambit Biosciences Corporation
Kern Medical Center
Investigators
Layout table for investigator information
Principal Investigator: Benjamin Wilke, MD Mayo Clinic

Additional Information:
Layout table for additonal information
Responsible Party: Benjamin K. Wilke, Principal Investigator, Mayo Clinic
ClinicalTrials.gov Identifier: NCT03845881    
Other Study ID Numbers: 18-004256
First Posted: February 19, 2019    Key Record Dates
Last Update Posted: May 10, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Analgesics, Opioid
Oxycodone
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents